PEGylated Recombinant Factor VIII
- Generic Name
- PEGylated Recombinant Factor VIII
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1417412-83-9
- Unique Ingredient Identifier
- 5X3GF74R79
- Background
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
- Associated Conditions
- -
- Associated Therapies
- -
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath